137 related articles for article (PubMed ID: 35351838)
21. Early Post-operative Stimulated Serum Thyroglobulin: Role in Preventing Unnecessary Radioactive Iodine Treatment in Low to Intermediate Risk Papillary Thyroid Cancer.
Sezer H; Yazıcı D; Terzioğlu T; Tezelman S; Canbaz HB; Yerlikaya A; Demirkol MO; Kapran Y; Çolakoğlu B; Çilingiroğlu EN; Alagöl F
Am Surg; 2023 Dec; 89(12):5996-6004. PubMed ID: 37309609
[TBL] [Abstract][Full Text] [Related]
22. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
23. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
Liu YQ; Li H; Liu JR; Lin YS
Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
[No Abstract] [Full Text] [Related]
24. Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.
Pitoia F; Abelleira E; Cross G
Endocrine; 2017 Jan; 55(1):200-208. PubMed ID: 27655291
[TBL] [Abstract][Full Text] [Related]
25. Thyroglobulin and 131I uptake of remaining tissue in patients with differentiated carcinoma after thyroidectomy.
Moser E; Fritsch S; Braun S
Nucl Med Commun; 1988 Apr; 9(4):262-6. PubMed ID: 3399222
[TBL] [Abstract][Full Text] [Related]
26. Thyroglobulin/thyrotropin ratio for predicting long-term response in differentiated thyroid carcinoma: a retrospective study.
De Marchi AF; de Macedo ABT; Soares CSP; Bolfi F; Iessi MRG; de Oliveira CC; Koga KH; Moriguchi SM; Tagliarini JV; da Silva Mazeto GMF
Arch Endocrinol Metab; 2021 Nov; 65(4):428-435. PubMed ID: 34283903
[TBL] [Abstract][Full Text] [Related]
27. A Retrospective Cohort Study with Validation of Predictors of Differentiated Thyroid Cancer Outcomes.
Wijewardene A; Gill AJ; Gild M; Learoyd DL; Glover AR; Sywak M; Sidhu S; Roach P; Schembri G; Hoang J; Robinson B; Tacon L; Clifton-Bligh R
Thyroid; 2022 Oct; 32(10):1201-1210. PubMed ID: 35620896
[No Abstract] [Full Text] [Related]
28. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment?
Tian T; Huang R; Liu B
Endocrine; 2019 Jul; 65(1):149-154. PubMed ID: 30924085
[TBL] [Abstract][Full Text] [Related]
29. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.
Yamazaki CA; Padovani RP; Biscolla RP; Ikejiri ES; Marchetti RR; Castiglioni ML; Matsumura LK; Maciel RM; Furlanetto RP
Thyroid; 2012 Oct; 22(10):1002-6. PubMed ID: 22953991
[TBL] [Abstract][Full Text] [Related]
30. Baseline stimulated thyroglobulin level as a good predictor of successful ablation after adjuvant radioiodine treatment for differentiated thyroid cancers.
Fatima N; uz Zaman M; Ikram M; Akhtar J; Islam N; Masood Q; Zaman U; Zaman A
Asian Pac J Cancer Prev; 2014; 15(15):6443-7. PubMed ID: 25124640
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathological, immunohistochemical factors and recurrence associated with extrathyroidal extension in papillary thyroid microcarcinoma.
Kim WY; Kim HY; Son GS; Bae JW; Lee JB
J Cancer Res Ther; 2014; 10(1):50-5. PubMed ID: 24762486
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer.
Lima N; Cavaliere H; Tomimori E; Knobel M; Medeiros-Neto G
J Endocrinol Invest; 2002 Feb; 25(2):110-5. PubMed ID: 11929080
[TBL] [Abstract][Full Text] [Related]
33. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
[TBL] [Abstract][Full Text] [Related]
34. Nomogram for Preoperative Estimation of Cervical Lymph Node Metastasis Risk in Papillary Thyroid Microcarcinoma.
Sun J; Jiang Q; Wang X; Liu W; Wang X
Front Endocrinol (Lausanne); 2021; 12():613974. PubMed ID: 33868164
[TBL] [Abstract][Full Text] [Related]
35. Stimulated Thyroglobulin and Thyroglobulin Reduction Index Predict Excellent Response in Differentiated Thyroid Cancers.
Barres B; Kelly A; Kwiatkowski F; Batisse-Lignier M; Fouilhoux G; Aubert B; Dutheil F; Tauveron I; Cachin F; Maqdasy S
J Clin Endocrinol Metab; 2019 Aug; 104(8):3462-3472. PubMed ID: 30785995
[TBL] [Abstract][Full Text] [Related]
36. A Phase II Multi-Center, Non-Randomized, Parallel Group, Non-Inferiority Study to Compare the Efficacy of No Radioactive Iodine Remnant Ablation to Remnant Ablation Treatment in Low- to Intermediate-Risk of Papillary Thyroid Cancer: The MOREthyroid Trial Protocol.
Lee EK; Lee YJ; Park YJ; Moon JH; Yi KH; Kim KS; Lee JH; Cho SW; Joo J; Hwangbo Y; Go S; Park DJ
Endocrinol Metab (Seoul); 2020 Sep; 35(3):571-577. PubMed ID: 32981299
[TBL] [Abstract][Full Text] [Related]
37. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
[TBL] [Abstract][Full Text] [Related]
38. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
Kim HJ; Kim NK; Choi JH; Kim SW; Jin SM; Suh S; Bae JC; Min YK; Chung JH; Kim SW
Clin Endocrinol (Oxf); 2013 Apr; 78(4):614-20. PubMed ID: 22957654
[TBL] [Abstract][Full Text] [Related]
39. Association between residual thyroid carcinoma and diffuse hepatic uptake of 131I following radioiodine ablation in postoperative total thyroidectomy patients.
Tatar FA; Morita E; Ituarte PH; Cavalieri RR; Duh QY; Price DC; Siperstein AE; Clark OH
World J Surg; 2001 Jun; 25(6):718-22. PubMed ID: 11376405
[TBL] [Abstract][Full Text] [Related]
40. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
